SCHEMBL10104044

SCHEMBL10104044

CC[C@H]1C[C@@H]1CO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11946140 1.00
SCHEMBL3795114 1.00
SCHEMBL11934324 1.00
SCHEMBL14347141 1.00
SCHEMBL12834846 0.86 EPHX2 (0.38)
SCHEMBL1935293 0.86 SI (0.34)
SCHEMBL1934212 0.86 SI (0.34)
SCHEMBL1934033 0.86 SI (0.34)
SCHEMBL1934214 0.86 SI (0.34)
SCHEMBL13167672 0.86 INPP5A (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240294876-A1 METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTE-MACROPHAGE PROGENITORS AND APPLICATIONS THEREOF UNIV SOUTHERN CALIFORNIA (US) 2024-09-05 US disclosed
EP-4341386-A2 METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTEMACROPHAGE PROGENITORS AND APPLICATIONS THEREOF University of Southern California (US) 2024-03-27 EP disclosed
CN-117751182-A Method for amplifying human granulocyte-macrophage progenitor cells and application thereof 南加利福尼亚大学 2024-03-22 CN disclosed
US-20230312490-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. 2023-10-05 US disclosed
US-11643400-B2 MCL-1 inhibitors GILEAD SCIENCES, INC. (US) 2023-05-09 US disclosed
WO-2022245977-A2 METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTEMACROPHAGE PROGENITORS AND APPLICATIONS THEREOF UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2022-11-24 WO disclosed
US-20170144973-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS Takenda Pharmaceutical Company Limited (JP) 2017-05-25 US disclosed
US-9650343-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-05-16 US disclosed
US-9630924-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-04-25 US disclosed
US-9573903-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-02-21 US disclosed
US-20160176873-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL (JP) 2016-06-23 US disclosed
US-20160176822-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL (JP) 2016-06-23 US disclosed
US-20160176872-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL (JP) 2016-06-23 US disclosed
US-9365520-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-14 US disclosed
US-20160002169-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-07 US disclosed
US-8101658-B2 Nitric oxide donating prostamides NICOX S.A. (FR) 2012-01-24 US disclosed
US-20110092590-A1 NITRIC OXIDE DONATING PROSTAMIDES NICOX S.A. (FR) 2011-04-21 US disclosed